Myriam Ouberai is the Founder and Chief Executive Officer of Spirea. Myriam holds a PhD in Chemistry and has significant experience in drug delivery and biopharmaceuticals in both academia and industry. Prior to Spirea, Myriam was a Senior Postdoctoral Research Associate at the University of Cambridge, Nanoscience Centre where her applied research included a significant collaboration with MedImmune-AstraZeneca. Her research, published in Nature Communications, also won the MedImmune 2017 Global Excellence Award for best publication. In 2018, Myriam was selected as one of 50 Movers and Shakers in BioBusiness by UK biotech platform BioBeat.